Seres Therapeutics CEO and leadership

As President and Chief Executive Officer of Seres Therapeutics, I’m focused on leading Seres with the belief that microbiome therapies can transform how disease is treated for individuals managing and living with serious disease. Through the combination of proprietary science, innovative technology and rigorous analysis, we’re striving to create a future that includes a revolutionary way of providing new treatment options to healthcare providers so patients can thrive from the inside out.My more than 20 years of experience working in executive leadership roles in biotechnology finance, corporate development and capital markets, drives me to help ensure Seres’ continued growth within the microbiome industry. Our steadfast commitment-from scientific discovery to fulfilling the promise of recovery-aims to help people live more fulfilling lives.

Geoffrey von Maltzahn, Ph.D. (born July 22, 1980) is an American biological engineer and entrepreneur in biotechnology and life sciences industry who has founded a number of companies including Indigo Agriculture, Sana Biotechnology, Kaleido Biosciences, Seres Therapeutics, Axcella Health and Tessera Therapeutics. He has 200 bioengineering and biotechnology patents and applications.

Matthew Henn is an Executive VP, Chief Scientific Officer at SERES THERAPEUTICS, INC. and Scientific Advisory Board at Growcentia, Inc and is based in Boston, Massachusetts. He has worked as Board Member at Viran Genomics Inc; Exec VP/Head:Microbiome Research at SERES THERAPEUTICS, INC.; and Research Scientist II at Broad Institute. Matthew works or has worked at Broad Institute of MIT and Harvard and works or has worked as FELLOW at NASA Earth Systems Sciences. He attended University of New Hampshire between 1993 and 1997, University of California Berkeley between 1997 and 2002, and West Morris Mendham High School.

Mr. Thomas DesRosier J. is an Executive Vice President, Chief Legal Officer and Secretary at SERES THERAPEUTICS, INC. and is based in Seres Therapeutics Inc..

Geoffrey von Maltzahn, Ph.D. (born July 22, 1980) is an American biological engineer and entrepreneur in biotechnology and life sciences industry who has founded a number of companies including Indigo Agriculture, Sana Biotechnology, Kaleido Biosciences, Seres Therapeutics, Axcella Health and Tessera Therapeutics. He has 200 bioengineering and biotechnology patents and applications.

As President and Chief Executive Officer of Seres Therapeutics, I’m focused on leading Seres with the belief that microbiome therapies can transform how disease is treated for individuals managing and living with serious disease. Through the combination of proprietary science, innovative technology and rigorous analysis, we’re striving to create a future that includes a revolutionary way of providing new treatment options to healthcare providers so patients can thrive from the inside out.My more than 20 years of experience working in executive leadership roles in biotechnology finance, corporate development and capital markets, drives me to help ensure Seres’ continued growth within the microbiome industry. Our steadfast commitment-from scientific discovery to fulfilling the promise of recovery-aims to help people live more fulfilling lives.